semaj83/ctmatch_classification huggingface dataset:
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-45.0,  Leukemia, Myeloid, Chronic Anemia, Aplastic Myelofibrosis Lymphoma Hodgkin Disease Leukemia, Lymphocytic, Chronic Leukemia, Myelocytic, Acute Leukemia, Lymphocytic, Acute One of the following diagnoses: 1. Chronic myelogenous leukemia (CML) accelerated phase or second stable phase; individuals in the first chronic phase are eligible if they have resistance to imatinib 2. Myelodysplasia 3. Aplastic anemia that is not responding to immunosuppressive therapy 4. Myelofibrosis, either primary or secondary to polycythemia vera 5. Relapsed lymphoma or Hodgkin's disease 6. Stage III/IV chronic lymphocytic leukemia (CLL), relapsed after or refractory to at least one fludarabine containing regimen 7. Acute myelogenous leukemia (AML) or acute lymphoblastic leukemia (ALL) in complete remission (CR) 2 or greater, or CR 1 with high risk features No prior autologous stem cell transplant Eastern Cooperative Oncology Group (ECOG) performance status of less than 2 Lack of 6/6 or 5/6 matched related donor OR lack of 10/10 matched unrelated donor OR no available donor in the appropriate time frame to perform a potentially curative stem cell transplant Diffusing capacity of the lung for carbon monoxide (DLCO) greater than 50% of predicted value Left ventricular ejection fraction (LVEF) greater than 50% of predicted value Calcium levels less than 10.5 mg/dl Phosphate levels greater than 1.6 mg/dl  Heart disease, as determined by symptomatic congestive heart failure, radionuclide ventriculogram (RVG), or echocardiogram-determined LVEF of less than 50%, active angina pectoris, or uncontrolled high blood pressure Pulmonary disease, as determined by severe chronic obstructive lung disease, symptomatic restrictive lung disease, or corrected DLCO of less than 50% of predicted value Kidney disease, as determined by serum creatinine levels greater than 2.0 mg/dl Liver disease, as determined by serum bilirubin levels greater than 2.0 mg/dl (except in the case of Gilbert's syndrome or hemolytic anemia in which the bilirubin can be elevated greater than 2.0mg/dl), SGOT or SGPT greater than 3 times the upper limit of normal Neurologic disease, as determined by symptomatic leukoencephalopathy, active central nervous system (CNS) cancer, or other neuropsychiatric abnormalities that may prevent transplantation (previous CNS cancer and presently in CR is acceptable) HIV antibodies Uncontrolled infection Pregnant or breastfeeding
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  RENAL INSUFFICIENCY, CHRONIC Hyperparathyroidism, Secondary Serum 25-OH-Vit.D-levels < 60 ng/ml 2. Age > 18 years 3. dialysis treatment > 3 Months 4. signed written informed consent 5. Serum-Calcium-levels < 2,6 mmol/l within the last 4 weeks 6. Serum-Phosphate-levels < 7,0 mg/dl within the last 4 weeks 7. Ca x P-Product < 75 mg2/dl2 within the last 4 weeks  Serum 25-OH-Vit.-D-levels > 60 ng/ml 2. concommitant participation in another interventional trial 3. psychiatric disorders preventing from valid informed consent 4. Hyperphosphatemia (> 7,0 mg/dl) within the last 4 weeks 5. Hypercalcemia (> 2,6 mmol/l) within the last 4 weeks 6. Ca x P-Product > 75 mg2/dl2 within the last 4 weeks 7. pregnancy or lactation 8. known malignancy 9. liver disease, defined as 2-fold upper limit of ASAT-, or ALAT-levels 10. PTH levels < 50 pg/ml 11. current clinically relevant infections treated with antibiotic therapy and raised hsCRP levels 12. Chronic viral Infectious diseases (e.g. HIV, Hepatitis B or C) 13. Immunosuppressant Medication 14. known hematologic disorders, other than renal anemia 15. age below 18 years 16. known anaphylactic reaction against the study medication or other ingredients of the study drug preparation 17. renal calculus 18. Pseudohypoparathyroidism 19. Medication including cardiac glycosides 20. Sarkoidosis
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Osteoporosis Osteitis Deformans Parathyroid Diseases Clinical diagnosis of a metabolic bone disorder  none
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 50.0-999.0,  Osteoporosis Postmenopausal women (at least 12 months since last menstruation) BMD (L2-4) T-score between -1 and -3 (at least 20% of the enrolled patients must have a BMD (L2-4) T-score below -2,5) years of age BMI<30 kg/m2 Total S-Ca level within normal range Ability to read and understand the information given The patient has signed an informed consent form according to ICH E6 and local requirements before any study specific procedure is carried out Ability to comply with study procedures  History of prior fragility fracture (any fracture in wrist, hip or spine appearing after 40 years of age) History of alcohol or drug abuse Metabolic bone disease (e.g. pagets disease, bone cancer) History of VTE/DVT History of kidney transplant Bilateral oophorectomy Relevant and treated reduced kidney or liver function Any malignancy within the last 5 years (except basal cell carcinoma) Any chronic condition likely to affect absorption (e.g. Crohns disease, gluten enteropathy) Known genetic pre-disposition to VTE/DVT
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Acne sever acne  renal disorders gastrointestinal disorders skeletal disorders endocrine disorders drugs such as glucocorticoids , thiazide diuretics, mineral multivitamins, anti acids, tetracyclines
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 9.0-999.0,  Hypophosphatemia, Familial Hyperparathyroidism Diagnosis of XLH rickets Fasting serum calcium of 10.7 mg/dl or less Fasting PTH greater than 40 nleq/ml and less than 120 nleq/ml in the mid-molecule PTH assay at screening (upper limit of normal is 25 nleq/ml) Willing and able to participate in the trial Taking stable dose of standard therapy for XLH rickets for at least 2 months prior to study entry Concomitant therapy for XLH rickets will not be an  Parent or guardian willing to provide informed consent, if applicable Concomitant kidney failure (estimated creatinine clearance less than 60 cc/min or serum creatinine greater than 1.5 mg/dl) Serum 25-hydroxy vitamin D less than 20 ng/ml. Participants meeting this criterion will receive vitamin D3 supplementation for 3 months and then be rescreened Unable to comply with protocol and appropriate follow-up visits Treatment with agents that may affect skeletal metabolism, such as glucocorticoids and anticonvulsants
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Osteoarthritis Arthralgia Osteoarthritis of the knee Persistent osteoarthritic symptoms for at least 6 months Radiographic evidence of late stage osteoarthritis of the knee (stage III-IV) History of conservative management including pain medication and physical therapy  Anticoagulant treatment or history of hemophilia History or presence of rheumatic diseases leading to secondary osteoarthritis Presence of hematological, hepatic, renal or immunological disease Insulin-dependant diabetes mellitus Intraarticular injections or systemic application of corticosteroids during the 3 preceding months History of surgery of the affected knee during the last 3 months or joint replacement History of previous leech therapy Lack of informed consent
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Secondary Hyperparathyroidism Age older than 18 yrs On hemodialysis for at least 3 months (thrice weekly) iPTH >300pg/ml or histological evidence of secondary hyperparathyroidism Calcium > 8.1 mg/dl  Unstable clinical condition
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Chondrocalcinosis Patients diagnosed as having calcium pyrophosphate dihydrate deposition disease  Patients mimicking a rheumatoid arthritis disease, with positive rheumatoid factor or with psoriasis
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Chronic Obstructive Pulmonary Disease Hyperglycemia Patients who are NOT diabetic, admitted with COPD who are likely to be prescribed corticosteroids as part of usual care with an admission glucose level (before steroids) between 6.1 and 11.1 mmol/l  Patients with diabetes mellitus Patients who are nil by mouth Patients with severe co-morbid disease with an anticipated life expectancy of < 6 months Patients who are unable to provide informed consent Age <18 years
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-79.0,  Osteoporosis Informed consent: Subject is willing and able to provide written informed consent Menopausal status: Ambulatory female aged < 80 years at screening and >5 years postmenopausal T-Score: A subject with either no or only one prevalent vertebral fracture is eligible for if she satisfies one of the following T-score requirements: If no prevalent vertebral fracture subject must have an absolute BMD value consistent with a T-score of less than or equal to -2.5 and greater than -4.0 at either the femoral neck, total hip, trochanter, or lumbar spine, or If one prevalent vertebral fracture subject must have an absolute BMD value consistent with a T-score of less than or equal to -2.0 and greater than -4.0 at either the femoral neck, total hip, trochanter, or lumbar spine Suitable vertebra: Two or more vertebra in the range of L1 to L4 that are suitable for BMD measurement by DXA Protocol compliance: Subject who, in the opinion of the investigator, is willing and able to comply with the requirements of the protocol T-Score: Has an absolute BMD value consistent with a T-score less than or equal to -4.0 at either the femoral neck, total hip, trochanter, or lumbar spine Vertebral fractures: Has >1 prevalent vertebral fracture at the screening visit Non-vertebral fractures: Any previous non-vertebral osteoporosis related/fragility fracture after age 40 Spine deformity: Significant spine deformity which would preclude DXA/QCT assessments BMI: BMI ≥33kg/m2  do not apply to subjects allocated to the open-label teriparatide group Calcium channel blockers: Current therapy with calcium channel blockers diltiazem and verapamil Oral Azole Antifungals: Current therapy with any oral azole antifungal Immunosuppressants: Current therapy with cyclosporine or oral tacrolimus Ritonavir: Current therapy with ritonavir Quinidine: Current therapy with quinidine Macrolide Antibiotics: Subjects anticipated to require chronic use of macrolide antibiotics Alendronate Contraindications: Contraindications to therapy with alendronate. Additional for Subjects Recruited at QCT Sites Hip surgery: History of hip surgery resulting in a metal implant on either the left or right side that would cause an artefact on a QCT scan. Additional
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  End-Stage Renal Disease years or older Chronic Hemodialysis for more than 3 months iPTH levels ≥ 300 pg/ml in the absence of therapy: Cinacalcet (Sensipar ®) and/or 1,25 Vitamin analogues (Zemplar®) Corrected Ca ≥ 8.4 mg/dl at time of enrollment Ability to stay at least 3 hours during hemodialysis treatment  Pediatric Patients (age ≤ 18 years) Those unable to give informed consent Dialysis treatment for less than 3 months, or pre-emptive kidney transplantation Inability to stay more than 3 hours during a single hemodialysis treatment period
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-50.0,  Postpartum Haemorrhage Any pregnant woman expected to deliver vaginally 2. Age more than 21 if not married 3. Ability to provide informed consent  Multiple pregnancy 2. Patients with other risk factors for postpartum haemorrhage 3. Patients planning to have an elective caesarean section 4. History of vascular disease such as coronary artery disease 5. History of hypertension requiring treatment within the last 2 years 6. History of hepatic or renal disease 7. Known or suspected coagulopathy 8. History of hypersensitivity to oxytocin or carbetocin 9. Any condition where the use of syntometrine/carbetocin is contraindicated
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Arthritis Arthralgia Females cannot become pregnant while participating in study Have a history of plaque psoriasis for at least 6 months Receiving or about to receive efalizumab for the treatment of chronic plaque psoriasis Have mild to moderate arthritis or arthralgia occurring while on treatment with efalizumab or untreated mild to moderate arthritis or arthralgia present at the time of initiating treatment with efalizumab  Previous systemic treatment with biologics other than efalizumab, within 3 months Treatment with any systemic corticosteroids or intra-articular corticosteroid injection, cyclosporine or methotrexate within 28 days Any previous treatment with chlorambucil or cyclophosphamide Have active tuberculosis or are currently receiving treatment or prophylactic therapy for tuberculosis Have other serious disorders; such as, congestive heart failure, prior or current history of blood dyscrasia, or central nervous system demyelinating disorders Has a sensitivity, intolerance, or history of gastrointestinal bleeding associated with diclofenac, indomethacin, and/or ibuprofen
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 21.0-999.0,  Fibromyalgia Age 21 or older Fulfills the American College of Rheumatology (ACR) 1990 diagnostic for FM. (1) a history of widespread musculoskeletal pain on the right and left sides of the body as well as above and below the waist for a minimum duration of 3 months, and (2) pain in 11 or more of 18 specific tender points with moderate or greater tenderness reported upon digital palpation Physically able to participate in both the Tai Chi and stretching and education programs according to their primary care physician Willing to complete the 12-week study, including twice-a-week Tai Chi or stretching and education sessions  Prior experience with Tai Chi or other similar types of Complementary and Alternative Medicine in the past 6 months such as Qi gong and yoga since these share some of the principles of Tai Chi Any health condition limiting the ability to participate as determined by a primary care physician Any other diagnosed medical condition that is known to contribute to FM symptomatology that is not under adequate control or cannot be expected to remain under adequate control for the study period such as thyroid disease, inflammatory arthritis, scleroderma, systemic lupus erythematosus, systemic sclerosis, rheumatoid arthritis, myositis and vasculitis or Sjogren's syndrome Not English-Speaking Positive pregnancy test or planning pregnancy within the study period Inability to pass the Mini-Mental Status examination (score below 24) Enrollment in any other clinical trial within the last 30 days Plan to permanently relocate from the region during the trial period
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Arthritis Joint Pain Age at or over 18 Indication for peripheral arthrocentesis  Hemodynamic instability Previous arthroplasty of the joint Known intraarticular fracture Hip arthrocentesis
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 35.0-70.0,  Hot Flashes Night Sweats Female ages 35-70, inclusive Postmenopausal (Natural or surgical: see definitions) Currently on HT/ET for at least 6 months for vasomotor symptomatology Vasomotor symptoms are currently controlled on medication  An annual physical & pelvic exam has been performed within the last 12mo The patient has had a normal mammogram(BIRADS I/II) within the last 24mo  Males Hypertension, defined as either SBP >140 mmHg or DBP >90 mmHg Lack of compliance (willingness to adhere to protocol) Inability or unwillingness to swallow pills Patients with any contraindications to HT/ET
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 2.0-999.0,  Obesity Prevention & Control Postpartum Period Recent delivery of a baby (~6 months ago) A preschooler in the home (2-5 years old), and a current BMI ≥25 (with confirmatory BMI ≥25 measured at baseline Knowledge of English Regular access to a telephone and mailing address Mother's age of 18 or older Willingness to participate in a healthy lifestyle correspondence and telephone intervention  Not meeting Medical conditions preventing mother from walking a mile without assistance Conditions preventing the child from regular activity
Patient description: Patient is a 34-year-old woman from Jordan who comes to clinic with some general and non-specific bones and joints pain. She is married and has 3 children. Her past medical and drug history are unremarkable. Her BMI is 23, BP: 120/75, HR: 75/min. Her laboratory study is remarkable for Vit D: 14ng/ml and otherwise healthy. (Ca: 9.2mg/dl, Phosphorus: 3.2mg/dl, PTH: 28pg/ml)

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Hyperparathyroidism Persons with parathyroid disease  None